Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction. by Carr, M. et al.
Britsh Journal of Cancer(1995) 72, 1427-1434
© 1995 Stockton Press All rights reserved 0007-0920/95 $12.00 00
Determination of oestrogen responsiveness of breast cancer by
competitive reverse transcription-polymerase chain reaction
M Carr', FEB May', TWJ Lennard2 and BR Westley'
'Department ofPathology, Royal Victoria Infirmary, Newcastle upon Tyne NE] 4LP; 2Department ofSurgery, Medical School,
Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Summary Competitive polymerase chain reaction assays have been developed for the quantitation of oestro-
gen receptor mRNA and two oestrogen-regulated mRNAs (progesterone receptor and pNR-2/pS2) in breast
cancer cells. These assays are more sensitive than traditional hybridisation techniques, do not require the use
of radioisotopes, measure absolute amounts of messenger RNAs and can be used to measure the expression of
mRNAs in small numbers of tumour cells obtained by fine-needle aspiration (FNA). These assays should
prove useful for predicting the hormone responsiveness of breast cancer from tumour cells obtained by FNA
at diagnosis and could be particularly useful in the management of elderly/frail patients who receive primary
tamoxifen, or in other patients for whom tumour tissue for standard biochemical measurements is not
available.
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Breast cancer is frequently oestrogen responsive and this has
resulted in the widespread use of hormonal therapy in its
treatment. The most commonly used endocrine agent is the
anti-oestrogen, tamoxifen, which has traditionally been used
to provide low toxicity palliation in women with advanced
breast cancer (Manni, 1989). More recently, it has been
shown to be highly effective at reducing mortality when used
as adjuvant therapy (Early Breast Cancer Trialists' Colla-
borative Group, 1992) and has been used as primary therapy
for treating elderly women (Gazet et al., 1988, Bates et al.,
1992).
Tamoxifen therapy is frequently of long duration and is
not without side-effects. In addition, a significant proportion
of women do not respond to endocrine therapy. There is
therefore considerable interest in predicting accurately the
likely benefit of tamoxifen therapy. Knowledge of the poten-
tial benefit to individual patients might avoid overtreatment
and permit the most appropriate form of therapy to be used
from the outset.
Several markers of oestrogen responsiveness in breast
cancer have been described. The oestrogen receptor was the
first, and approximately one-half of women with oestrogen
receptor-positive primary tumours respond to tamoxifen on
relapse (McGuire et al., 1975). The oestrogen receptor
mediates the effects of oestrogens on tumour cells and cont-
rols the expression of a number of genes by oestrogen, some
of which may provide improved markers of oestrogen res-
ponsiveness. The progesterone receptor, which mediates the
effects of progestins, and the pNR-2/pS2 protein, a 'trefoil'
peptide of unknown function (Poulsom and Wright, 1993),
are both induced by oestrogens in oestrogen-responsive
breast cancer cells in culture (Horwitz and McGuire, 1978;
May and Westley, 1988). Expression of both proteins is
associated with responsiveness to endocrine therapy (Osborne
et al., 1980; Henry et al., 1991), although the relative merits
of these markers remain unclear.
There are a number of clinical situations in which it would
be beneficial to be able to predict oestrogen responsiveness
using tumour cells obtained by fine-needle aspiration (FNA)
at the time of diagnosis. For instance, elderly women who
receive primary tamoxifen have tumour cells removed by
FNA for diagnosis, but their tumour is not removed sur-
gically and tissue samples are not therefore available for
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biochemical analysis. Among breast cancers diagnosed by
screening, there is a significant proportion which do not
provide sufficient material for conventional biochemical
measurements. In addition, it is possible that in the future,
small lesions will be destroyed in situ by techniques such as
laser diathermy.
Among the techniques which allow the measurement of
gene expression in small numbers of cells, reverse transcrip-
tion-polymerase chain reaction (RT-PCR) potentially pro-
vides a rapid, sensitive method for measuring mRNA levels.
The rate at which PCR products accumulate, however,
depends on a variety of factors, including the sequence being
amplified, the sequences of the PCR primers as well as the
concentration of divalent cations, buffer composition and the
type of reaction tube and thermocycler used. Because of the
large number of variables, estimation of the amount of an
mRNA put into a PCR reaction from either the amount of
product at the end or the rate of accumulation of product
during a PCR reaction is not trivial. A number of strategies
have been described recently which attempt to overcome
these problems (e.g. Hoof et al., 1991; Apostolakos et al.,
1993; Clifford et al., 1994) and allow the quantitation of
mRNA levels. In this report we describe the development of
competitive RT-PCR assays based on the procedure des-
cribed by Becker-Andre and Hahlbrock (1989), for the
measurement of oestrogen receptor, progesterone receptor
and pNR-2/pS2 mRNA levels in RNA extracted from small
numbers of breast cancer cells.
Materials and methods
Cell culture
MCF-7, T47D, EFM-19 and MDA-MB-231 human breast
cancer cells were cultured as described previously (May and
Westley, 1986; Johnson et al., 1989). In experiments in which
RNA levels were measured in oestrogen- and tamoxifen-
treated cells, MCF-7 cells were first withdrawn from oestro-
gens present in routine culture medium and then stimulated
with oestradiol and tamoxifen, also as described previously
(May and Westley, 1988; Johnson et al., 1989).
RNA extraction
Total RNA was extracted from cultured breast cancer cells
and breast tumour cells obtained by FNA using aMeasurement of oestrogen response by RT-PCR
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modification of the method of Chomczynski and Sacchi
(1987).
Cell monolayers were washed twice with phosphate-buffer-
ed saline (PBS) and lysed with 1 ml of guanidinium thio-
cyanate (4 M), lauryl sarcosine (0.5%), 2-mercaptoethanol
(0.1 M), sodium citrate (25 mM) pH 7.0. Sodium acetate
(100jil of 2M, pH 4.0), water-saturated phenol (1 ml) and
chloroform-isoamyl alcohol (49:1, 250t) were added
sequentially with vigorous mixing after each addition. The
aqueous and organic phases were separated by centrifugation
and the RNA was recovered from the aqueous phase by
ethanol precipitation. The RNA was redissolved in 50pLI of
guanidinium thiocyanate lysis solution and then reprecipit-
ated by the addition of two volumes of ethanol. The
precipitated RNA was dissolved in 100 lI Tris-HCI (1 mM
pH 8.0).
Tumour cells obtained by FNA were flushed from the
syringe needle into 1 ml of Tris-buffered saline in a cryotube
and centrifuged. The Tris-buffered saline was then removed
and the cells stored in liquid nitrogen until extraction. RNA
was extracted from tumour cells as described above except
that the volumes of all reagents used for the extraction were
reduced 10-fold.
cDNA cloning, site directed mutagenesis andpreparation of
competitor RNA
The 1.8 kb EcoRI fragment of oestrogen receptor cDNA was
transferred from the plasmid pKCR2 (Green et al., 1986) to
the plasmid KSM13-. Progesterone receptor cDNA (nucleo-
tide 2285-2473; Kastner et al., 1990) was amplified by RT-
PCR from RNA extracted from T47D cells and cloned into
the SmaI site of KSM13-. The pNR-2/pS2 plasmid, which
contains all but 25 nucleotides at the 5' end of the pNR-2/
pS2 mRNA, was isolated by differential screening of a cDNA
library prepared from ZR-75 breast cancer cells (May and
Westley, 1986; Piggott et al., 1991). It was transferred from
pUC19 into KSM13- as a BamHI/EcoRI fragment.
BamHI sites were created within cloned cDNAs using in
vitro mutagenesis as described by Kunkel et al. (1987).
Single-stranded DNA for in vitro mutagenesis was produced
by single-stranded rescue in Escherichia coli CJ236. The
mutagenic primers were 5'-GGTCTTTTC GGATCC GAC-
CTT-3' for the oestrogen receptor, 5'-GAGGCC GGATCCA
GAAGCCAG-3' for the progesterone receptor and 5'-
GCGTCA GGATCC CAGGCAGATC-3' for pNR-2/pS2.
The nucleotide being mutated is underlined.
Competitor RNA was synthesised from linearised, mutated
plasmids using T7 DNA-dependent RNA polymerase. The
mutated oestrogen receptor plasmid was linearised by KpnI,
the mutated progesterone receptor plasmid by EcoRI and the
mutated pNR-2 plasmid by HindIIl.
Competitive RT-PCR
Primer pairs for PCR were selected by computer program
(Diamond et al., 1990).
For the oestrogen receptor, the 5' sense primer (5'-
ACGACTATATGTCCAGCC-3') and the 3' antisense
primer (5'-AGGTTGGCAGCTCTCATGTCTCC-3') amplify
a target sequence of 223 nucleotides from bases 882-1104 of
the mRNA. The 5' sense primer for the progesterone recep-
tor (5'-GCTCCCGCAGCTCGGCTACC-3') and the 3'
antisense primer (5'-ACAGCCTGATGCTTCATCCCC-3')
amplify a target sequence of 174 bp from bases
2285-2473 of the mRNA. For the pNR-2/pS2 mRNA a
target sequence of 248 bp is amplified by the 5' (5'-
ATAAGGGTGCTGTTTCGAC-3') and 3' (5'-GTCAGAG-
CAGTCAATCTGTG-3') primers from bases 198-445 in the
mRNA sequence.
Cellular RNA (100 ng) and varying amounts of synthetic
competitor RNA were reverse transcribed in 10 1l of potas-
sium chloride (75 mM), magnesium chloride (1OmM), DTT
(10mM), Tris-HCI (50 mM, pH 8.0) containing 0.5 mM of
each dNTP, 100 ng of random hexamer primers, four units
of RNase inhibitor and eight units of Moloney murine
leukaemia virus reverse transcriptase. The reaction was
incubated at 37°C for 1 h.
The reverse transcription reactions were diluted 10-fold in
water and 2 p1l aliquots amplified by PCR in a reaction
volume of 25 .lI containing buffer (Tris pH 8.3, 10 mM;
potassium chloride, 50 mM; magnesium chloride 1.5 mM;
gelatin, 0.001%), bovine serum albumin (100 lgml-'),
dATP, dCTP, dGTP and TTP (0.2 mM ofeach), forward and
reverse primers (100 ng of each) and Taq polymerase (0.75
units). Reactions were overlaid with mineral oil. In the first
two cycles, samples were denatured for 90 s at 94°C, annealed
for 30s at 60°C and extended for 30 s at 72°C. For the
remaining 38 cycles samples were denatured at 92C for 30 s,
annealed at 60°C for 30 s and extended at 72°C for 30 s. The
extension time was increased to 120 s in the final cycle.
An aliquot of 5 p1 of each PCR reaction was digested for
3 h at 37°C with five units BamHI. The digested products
were electrophoresed on a 2% nusieve/1% agarose gel and
stained with ethidium bromide. The intensities of the bands
corresponding to the digested and undigested PCR products
were measured using a Millipore Bio-Imager and the quan-
tity of mRNA in the original extract of RNA calculated as
described in the Results section. The values obtained when
assays were repeated, varied by a maximum of 14% from
those shown in the results section.
Results
Selection oftarget sequences, andpreparation ofmutated RNA
for competitive RT-PCR
The method described by Becker-Andre and Hahlbrock
(1989) for quantitating mRNAs involves the introduction of
known amounts of synthetic competitor RNA into reverse
transcription reactions containing equal amounts of cellular
RNA. The competitor RNA differs from the normal cellular
RNA being measured by a single nucleotide and the single
nucleotide difference is sufficient to introduce a restriction
enzyme site into the centre ofPCR products derived from the
competitor RNA. Aliquots of the reverse transcription reac-
tion are amplified by PCR and then digested with the restric-
tion enzyme. The proportion ofdigested and undigested PCR
product is then determined by densitometry of ethidium
bromide-stained agarose gels. The amount of the target
mRNA in the sample can then be calculated as described
below.
This method therefore requires that the target sequence in
the mRNA being measured contains a sequence that can be
converted to a unique restriction enzyme site by in vitro
mutagenesis of a plasmid containing the corresponding
cDNA. In addition, the target sequences chosen should be
short enough (approximately 200 bp) to facilitate efficient
amplification using short extension times, long enough to
allow easy separation of undigested and digested PCR pro-
ducts by gel electrophoresis and be interrupted by at least
one intron to ensure that the PCR products are derived from
RNA rather than contaminating cellular DNA.
The sequences of the primers, together with the size of the
target sequence and the mutation made to the cDNA are
shown in Table I. cDNA corresponding to the three mRNAs
measured in this study was inserted into the plasmid
KSM13- to allow the production of single-stranded DNA
for in vitro mutagenesis by plasmid rescue and the synthesis
of competitor RNA in vitro by transcription from the T7
promoter which is adjacent to the multiple cloning site. The
cDNA inserts, together with the PCR target sequences and
the positions of the engineered restriction enzyme site are
shown diagrammatically in Figure 1. The target sequence
selected for the oestrogen receptor was located towards the
C-terminus of the DNA-binding domain and traversed the
third intron which is more than 32 kb long. For the pro-
gesterone receptor, the target sequence was located at the
C-terminus of the B region and traversed the intron located
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Table I
Size of PCR
Primer sequences fragment New restriction Restriction fragment
mRNA 5'-*3' (nucleotides) Mutation site sizes (nucleotides) References
Oestrogen ACGACTATATGTCCAGCC 223 A997->C BamHI 114, 109 Green et al. (1986)
receptor AGGTTGGCAGCTCTCATGTCTCC
Progesterone GCTCCCGCAGCTCGGCTACC 174 T2388-*C BamHI 88, 86 Kastner et al. (1990)
receptor ACAGCCTGATGCTTCATCCCC
pNR-2/pS2 ATAAGGGTGCTGTTTCGAC 248 C319->G BamHI 123, 125 Jackolew et al. (1986)
GTCAGAGCAGTCAATCTGTG
1429
800 bp BamHI fragment
BamHI
BamHI A .1 BamHI ~~~~882 1104
[223bp 2031
218 684 875 LI 1328 1467 1601 992
ABamH digestion
Oestrogen receptor cDNA
100 bp
BamHI fragment
BamHI
T238 C
2285 2473
BamHI
1ia74 bp|
2285 a 2473
2380
,/kBamHI digestion
Progesterone receptor cDNA
330 bp
BamHI fragment
BamHI
BamHI 198 C wG445
26126 a
278
kamHI digestion
|123bpl 123b
pNR-2/pS2 cDNA
Figure 1 Plasmids used for the preparation ofmutated RNA for
competitive RT-PCR. The plasmids containing oestrogen recep-
tor, progesterone receptor and pNR-2/pS2 cDNA are illustrated.
Numbers above the cDNA give the position of the target
sequence within the mRNA. Numbers below the cDNA show the
mRNA sequence contained within the cDNA clone and the
numbers under the inverted arrows indicate the positions of
introns. MCS shows the position of the multiple cloning site
containing the BamHI site within the vector. The target sequence
amplified by PCR and its length is indicated. The mutation used
to create the BamHI site is shown above the centre of the target
sequence. The length of the BamHI fragment after digestion of
the mutated plasmid is shown above the cDNA and the
fragments generated by BamHI digestion of the PCR products
amplified from mutated RNA are shown below; the length of
each fragment is given.
at position 2380 in the mRNA sequence. The target sequence
for pNR-2/pS2 contained the C-terminal half of the protein
and most of the 3' non-coding region and traversed the
second intron which is located at position 278 in the mRNA
sequence.
BamHI sites were generated by site-directed mutagenesis as
described in Materials and methods at the positions shown in
Table I and Figure 1. The parent and mutated plasmids
- 800
- 330
- 100
A997 c997 T2388 C2388 C319 G319
-N
I
Oestrogen Progesterone pNR-2/pS2
receptor receptor
Figure 2 Mutation of plasmids used to synthesise competitor
RNA for RT-PCR. Mutations (A17+C for oestrogen receptor,
T2388+C for progesterone receptor and C3'9->G for pNR-2/pS2)
were introduced by site-directed mutagenesis. The unmutated and
mutated plasmids were digested with BamHI and the digested
DNA analysed by agarose gel electrophoresis. The sizes of the
fragments produced by digestion of the mutated plasmids are
shown on the right.
corresponding to each of the three target mRNAs were
digested with BamHI to verify the presence of the new
BamHI restriction site in the desired location of the mutated
plasmids (Figure 2). All three parent plasmids contain a
BamHI recognition sequence within the multiple cloning site
of the plasmid but no BamHI site within the cDNA insert
and are therefore linearised by BamHI (Figures 1 and 2). As
predicted (Figure 1), BamHI digestion of the mutated oestro-
gen receptor plasmid liberates a fragment of approximately
800 bp, digestion of the mutated progesterone receptor plas-
mid liberates a small fragment of approximately 100 bp,
corresponding to half the length of the target sequence, while
digestion of the mutated pNR-2/pS2 plasmid liberates a frag-
ment of approximately 330 bp (Figure 2). The mutated plas-
mids were linearised and synthetic RNA was transcribed
from the three mutated cDNAs using T7 DNA-dependent
RNA polymerase as described in Materials and methods.
Establishment ofcompetitive RT-PCR assays
The competitive RT-PCR assays for the oestrogen receptor,
progesterone receptor and pNR-2/pS2 mRNAs were tested
on cellular RNA extracted from the oestrogen-responsive
MCF-7 and non-responsive MDA-MB231 breast cancer cell
lines. Five reverse transcription reactions, each containing
100 ng of total cellular RNA supplemented with various
amounts of synthetic mutated RNA were performed for each
cell line as described in Materials and methods. Following
amplification by PCR and subsequent BamHI digestion, the
products were separated by agarose gel electrophoresis
(Figure 3). For all three mRNA assays, two bands were
obtained from the MCF-7 RNA. The amount of digested
PCR product predominates in reactions supplemented with
higher amounts of mutated competitor RNA because there is
insufficient cellular mRNA present to compete with the
mutated RNA. In reactions supplemented with low levels of
mutated competitor RNA, the cellular mRNA is in excess
and only the undigested PCR product is visible. MCF-7
RNA was estimated to contain 98 fg of oestrogen receptorMeasurement of oestogen response by RT-PCR R M Carr etal
mRNA, 217 fg of progesterone receptor mRNA and 4 pg of
pNR-2/pS2 mRNA per 100 ng RNA from analysis of the
gels as described below. Digestion of PCR products derived
from MDA-MB231 cells gave rise to only the faster migrat-
ing band showing that this cell line contains undetectably low
concentrations of oestrogen receptor, progesterone receptor
and pNR-2/pS2 mRNA.
Calculation ofoestrogen receptor, progesterone receptor and
pNR-2/pS2 mRNA levelsfollowing competitive RT-PCR
The amounts of cellular and competitor RNA are not
directly equivalent to the amounts ofundigested and digested
PCR product. Denaturation and renaturation of the PCR
products in the final cycles of the PCR reaction (when little
new synthesis occurs) allows heteroduplexes to form between
PCR products derived from the cellular and competitor
RNA. Whereas homoduplexes derived from the mutated
RNA are digested by the restriction enzyme, heteroduplexes
between the PCR products derived from the cellular and
mutated RNAs are not and are indistinguishable from
homoduplexes derived from cellular mRNA. Therefore the
slower migrating band corresponding to non-digested PCR
products contains heteroduplexes of cellular and mutated
RNA PCR products as well as homoduplexes of PCR pro-
ducts of non-mutated cellular RNA.
By the end of the PCR reaction, the single-stranded PCR
products are randomly distributed between homoduplexes
and heteroduplexes. The relative amounts of the two homo-
duplexes and the heteroduplex can be calculated using the
Hardy-Weinberg equation which relates the frequency of
homozygotes and heterozygotes to the abundance of an allele
in a population:
c2+2cm+m2 = 1
where c is the proportion of PCR product derived from the
cellular mRNA and m is the proportion of PCR product
derived from the competitor mutated RNA.
m2 represents the fraction of PCR product in the form of
homoduplexes of molecules derived from the mutated RNA.
c2 represents the fraction of PCR product in the form of
homoduplexes of molecules derived from cellular RNA. 2 cm
is the fraction of PCR product in the form of heteroduplexes
between molecules derived from the mutated and cellular
RNA. As homoduplexes of molecules derived from the
mutated RNA (m2) are cut by the restriction enzyme whereas
homoduplexes derived from cellular RNA (c2) and
heteroduplexes (2 cm) are not, the ratio of
undigested-digested product is equivalent to c2 + 2 cm:m2.
When there are equal amounts of digested and undigested
PCR products, m2 = 0.5 and therefore m = 0.71. As
m + c = 1, then c = 0.29. Thus 71% of the PCR product is
derived from mutated RNA while 29% is derived from the
cellular RNA. Therefore, once the amount of synthetic RNA
that must be added to the reverse transcription to produce
equal amounts of digested and undigested PCR products is
known, the amount of cellular mRNA present in the reverse
transcription can be calculated by multiplying this amount by
29/71 = 0.41.
In practice, as can be seen in Figure 3, the competitive
RT-PCR reactions do not usually produce bands of equiva-
lent intensity. The amount of mutated RNA required to give
equal amounts of digested and undigested product is
obtained by interpolation and various ways of plotting the
data generated by this assay were therefore investigated.
Theoretical curves were generated for the measurement by
RT-PCR of 1 (V), 5 (U) and 25 (-) ng of non-mutated
RNA in the presence of 0.1-100 ng of competitor mutated
RNA. The equation, c2 + 2 cm + M2 = 1 was used to cal-
culate the amount of digested and undigested PCR product
for each hypothetical RT-PCR. The ratio of the amount of
undigested and digested PCR products was plotted against
the amount of competitor RNA added. When the data were
plotted using linear or log-linear axes, the curves were non-
linear and the data highly compressed. Figure 4 shows the
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Figure 3 Competitive RT-PCR for oestrogen receptor, pro-
gesterone receptor and pNR-2/pS2 RNAs in MCF-7 and MDA-
MB231 breast cancer cell RNA. An aliquot of 100 ng of cellular
RNA from either MCF-7 or MDA-MB231 cells was supple-
mented with the indicated amount of mutated competitor RNA,
reverse transcribed, amplified by PCR and digested by BamHI as
described in the Materials and methods. The BamHI-digested
PCR products were then separated by agarose gel electrophoresis
and stained with ethidium bromide.
data plotted using logarithmic axes which produces near-
linear curves over the complete concentration range of com-
petitor RNA. In addition, the curves corresponding to the
different amounts of cellular RNA are parallel and allow the
amount of added mutated RNA required to give bands of
equal intensity to be easily determined.
The amount of the mRNA is then calculated by multiply-
ing this figure by 0.41 as described above. In practice, a
further correction is usually required because the cloned
cDNA from which the competitor RNA is synthesised is
usually shorter than the cellular mRNA. The correction fac-
tors for oestrogen receptor, progesterone receptor and PNR-
2/pS2 are 3.4, 53 and 1.1 respectively.
Measurement ofoestrogen receptor, progesterone receptor and
pNR-2/pS2 mRNA levels in breast cancer cell lines
To explore whether the RT-PCR assays could reliably
measure different amounts of mRNA, pNR-2/pS2 mRNA
levels were measured in reverse transcription reactions con-
taining 4, 20 and 100 ng of total RNA extracted from MCF-Measurement ofoestgen response by RT-PCR
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Figure 4 Theoretical curves of ratio of undigested and digested
PCR product plotted against the amount of comnpetitor RNA.
The proportion of digested and undigested PCR product were
calculated when 0.1-100 ng of competitor mutant RNA was
added to 1 (v), 5 (v) and 25 (@)ng of an RNA using the
equation c2 + 2 cm +M2= 1 where m is the proportion of
mutated RNA and c is the proportion of unmutated RNA in the
RT-PCR. The axes are plotted on log scales. The horizontal
dashed line represents equal amounts of digested and undigested
PCR product (ratio = 1) and the vertical line shows that the
amount of mutant added is 0.41 times the amount required to
give equal amounts of digested and undigested PCR product.
7 cells. Figure 5 shows the log of the ratio of undig-
ested-digested PCR product (log c2 + 2 cm/M2) plotted
against the log of the amount of the competitor RNA (log
m). Data are not plotted when only one PCR band is visible
(resulting from a large excess of cellular or competitor RNA)
as the ratio is meaningless (zero or infinity).
The amount of pNR-2/pS2 mRNA present in each sample
of MCF-7 RNA was calculated as described in the previous
section. This gave values of 0.09 pg pNR-2/pS2 RNA 4 ng-',
0.6 pg pNR-2/pS2 RNA 20 ng-' and 3.4 pg pNR-2/pS2
RNA 100 ng-' of MCF-7 RNA. These values are in close
agreement and demonstrate that this RT-PCR assay is inter-
nally consistent over a 25-fold range of input RNA.
The concentrations of the oestrogen receptor, progesterone
receptor and pNR-2/pS2 mRNAs were then measured in
100 ng total RNA extracted from three oestrogen-responsive
(MCF-7, EFM-19 and T47D) and one non-responsive
(MDA-MB-231) breast cancer cell lines. The amount of each
mRNA in the four cell lines is shown in Table II. Oestrogen
receptor mRNA was present at highest levels in EFM-19
cells, slightly lower levels in MCF-7 and T47-D cells and was
not detected in MDA-MB231 cells. Progesterone receptor
mRNA was expressed at highest levels in T47-D cells, lower
levels in the other two oestrogen responsive cell lines but was
not detected in the MDA-MB231 cell line. The pNR-2/pS2
mRNA was the most abundant RNA and was expressed at
highest levels in MCF-7 cells, at approximately 3- and 30-
fold lower levels in EFM-19 and T47-D cells respectively and
was not detected in MDA-MB231 cells. These results are
similar to those in which the relative levels of the three
RNAs have been measured by hybridisation (May and West-
ley, 1988; May et al., 1989; Westley et al., 1989). However, as
well as their increased sensitivity, the RT-PCR assays have
the advantage that the absolute amount of each RNA can be
determined.
Use ofRT-PCR to measure the induction ofpNR-2 mRNA
by oestradiol and tamoxifen
To determine whether the competitive RT-PCR assays were
able to quantitate the effects of oestrogen and anti-oestrogens
on regulated mRNA concentrations, MCF-7 cells were with-
drawn from the oestrogens present in normal cell culture
medium by culturing in phenol red-free medium containing
charcoal-treated serum and then treated for 2 days with the
.I ,.
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Figure 5 Quantitation of pNR-2/pS2 mRNA concentrations in
varying amounts of MCF-7 mRNA. Aliquots of 4 (-), 20 (A)
or 100 (-) ng of MCF-7 RNA were supplemented with
50-0.08 pg of mutated competitor pNR-2/pS2 RNA and then
processed for RT-PCR as described in Materials and methods.
The ratio of undigested to digested PCR product was determined
and plotted against the amount of competing mutant RNA
added to the PCR reaction for those reactions in which the
intensity of both bands could be measured. The horizontal
dashed line represents equal amounts of digested and undigested
PCR product (ratio = 1) and the vertical dashed lines allow the
amount of mutant required to give equal amounts of undigested
and digested PCR product to be read off from the x-axis.
Table II Quantities of mRNAs in each of the four cell lines
ER PgR pNR-2/p2
(fg 100 ng-') (fg 100ng-') (pg 100ng-')
MCF-7 98 217 3.7
EFM-19 152 1073 1.2
T47-D 27 5438 0.1
MDA-MB-231 0 0 0
same medium containing oestradiol and tamoxifen. The con-
centrations of pNR-2/pS2 mRNA were then measured in
100 ng of total RNA by the competitive RT-PCR assay as
described above. Figure 6 shows the log of the ratio of
undigested-digested PCR product (c2 + 2 cm/iM2) plotted
against the log of the amount ofcompetitor RNA added (m).
pNR-2/pS2 mRNA was detectable at low levels, 2.96 pg 100
ng-' of total RNA in the withdrawn cells, at 6.8 pg 100 ng-'
in the cells treated with tamoxifen and at 164 pg 100 ng -'in
cells treated with oestradiol. Oestradiol therefore induced the
pNR-2/pS2 mRNA 60-fold in this experiment. Tamoxifen
had a small oestrogen agonist effect increasing pNR-2/pS2
mRNA concentrations 2.3-fold. This experiment shows that
the competitive RT-PCR assay can be readily used to detect
the induction of regulated mRNAs by steroids and gives
qualitatively similar results to those obtained previously by
hybridisation (May and Westley, 1987).
Measurement ofoestrogen receptor, progesterone receptor and
pNR-2/pS2 mRNA in RNA extractedfromfine needle
aspirates
The sensitivity of the competitive PCR assays suggested that
they would allow quantitation of mRNA concentrations in
tumour cells obtained by FNA. A small series of aspirates
were taken from breast cancers, a proportion of the cells
were examined histologically and RNA was extracted from
the remainder as described in Materials and methods. The
concentrations of the oestrogen receptor, progesterone recep-
tor and pNR-2/pS2 mRNAs were measured by competitive
PCR assay as described above. Figure 7 shows the results
from two representative aspirates.
All three mRNAs were detected in RNA extracted from
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aspirate 5. The concentration of oestrogen receptor mRNA
was 19 fg 100 ng'- total RNA, which is considerably lower
than in MCF-7 cells but is similar to the concentration
detected in the oestrogen-responsive cell line T47D. Of the
two oestrogen-regulated mRNAs, the progesterone receptor
mRNA concentration was 11 fg 100 ng-' which is lower than
in T47-D cells, higher than in MCF-7 cells and almost the
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Figure 6 Measurement of the induction of pNR-2/pS2 mRNA
in MCF-7 cells by oestradiol and tamoxifen using competitive
RT-PCR. An aliquot of 100 ng of RNA extracted from with-
drawn MCF-7 cells (-) or withdrawn MCF-7 cells that had been
stimulated with 1 lLM tamoxifen (A) or 10 nm oestradiol (0) for
2 days was supplemented with 50-0.08 pg of mutated competitor
pNR-2/pS2 RNA and the processed for RT-PCR as described in
Materials and methods. The ratio of undigested to digested PCR
product was determined and plotted against the amount of com-
peting mutant RNA added to the PCR reaction for those reac-
tions in which the intensity of both bands could be measured.
The horizontal dashed line represents equal amounts of digested
and undigested PCR product (ratio = 1) and the vertical dashed
lines allow the amount of mutant required to give equal amounts
of undigested and digested PCR product to be read off from the
x-axis.
same concentration as in EFM-19 cells. The pNR-2/pS2
mRNA was expressed at a relatively high level 2 pg 100 ng-'
in the tumour cells obtained from aspirate 5, which is nearly
as much as in MCF-7 cells. Thus the tumour cells obtained
from aspirate 5 express concentrations of the oestrogen
receptor mRNA and the two oestrogen-responsive mRNAs
similar to the concentrations expressed by three oestrogen-
responsive breast cancer cell lines. In contrast, none of the
three mRNAs were detected by the RT-PCR assays in RNA
extracted from aspirate 11 (Figure 7). The complete absence
of these three mRNAs is typical of the pattern of expression
found in cell lines such as MDA MB231 (Figure 3 and Table
I) whose growth is completely oestrogen independent.
Discussion
The ability to predict accurately the response ofbreast cancer
patients to anti-oestrogen therapy would be of undoubted
value in reducing overtreatment. The generally perceived
inaccuracy of current markers such as the oestrogen receptor,
progesterone receptor and pNR-2/pS2 protein has, however,
inhibited their widespread use in clinical practice. Most data
relating the expression of markers of oestrogen responsive-
ness to the clinical response to anti-oestrogens such as
tamoxifen is derived from studies in which the expression of
the marker was measured in the primary tumour but the
response to endocrine therapy was assessed in metastatic cells
following relapse. The lack of accuracy could, therefore, be
due to a change in the phenotype of the cells during disease
progression or could reflect an inherent inaccuracy of these
markers. Recent results in which elderly women have been
given tamoxifen as primary treatment have demonstrated
that oestrogen receptor (Davis et al., 1991) and pNR-2/pS2
(Wilson et al., 1994) expression accurately predict the res-
ponses of individual patients to tamoxifen, suggesting that
they are accurate markers as long as the measurements are
made at the time treatment is commenced. Although the
relative merits of the oestrogen receptor, progesterone recep-
tor and pNR-2/pS2 protein remain to be assessed the use of
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Figure 7 Measurement of oestrogen receptor, progesterone receptor and pNR-2/pS2 mRNA concentrations in breast cancer cells
obtained by fine needle aspiration. An aliquot of 100 ng of RNA extracted from two different aspirates was supplemented with the
indicated amount of mutated competitor RNA, reverse transcribed, amplified by PCR and digested by BamHI as described in
Materials and methods. The BamHI-digested PCR products were then separated by agarose gel electrophoresis and stained with
ethidium bromide.
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Ch e,. e% elk flV.these markers could revive the use of primary tamoxifen,
which has been criticised because of the unacceptably high
frequency of local recurrence in unselected patients (Dixon,
1992).
Comparison ofcompetitive PCR with other methods of
quantitative PCR
There have been numerous publications describing the use of
PCR for measuring the expression of mRNAs, including the
measurement of oestrogen receptor (Fuqua et al., 1990) and
pNR-2/pS2 mRNAs (Dante et al., 1994; Wundrack et al.,
1994) in a variety of tissues and tumours. Early studies used
the presence or absence of PCR products as a qualitative
measure of mRNA expression (Rappolee et al., 1988, 1989)
and these assays were originally referred to as mRNA
phenotyping. Subsequent protocols have attempted to intro-
duce an element of quantitation, the most commonly used
procedure being to measure the accumulation of PCR prod-
ucts from the mRNA being quantitated relative to the
accumulation of PCR products from a 'control' RNA. These
procedures measure relative RNA levels only and have three
disadvantages. The first is that there is little justification for
the assumption that the concentration of the control RNA
does not vary. The second is that the efficiency of reverse
transcription and amplification reactions can vary between
the mRNA being quantitated and the control RNA being
used, particularly if the reactions are performed in separate
tubes. The third is that many protocols require the use of
radioactive isotopes (either incorporated into the PCR prod-
uct or to label a probe which is then hybridised to the PCR
products).
In contrast, competitive RT-PCR measures the absolute
levels of RNAs because the amount of competitor RNA
added is known (Siebert and Larrick, 1992). The competing
RNA acts as an internal control for the reverse transcription
and PCR reactions and quantitation is completely indepen-
dent of variations in the efficiency of the reactions between
samples. In addition, this procedure does not use
radioisotopes since the PCR generates sufficient DNA to be
visualised directly on agarose gels.
Sensitivity ofcompetitive RT-PCR assays
The obvious advantage of PCR over hybridisation methods
for the detection of mRNAs is its extreme sensitivity. North-
ern hybridisation and RNase protection assays require 10-20
ig of total RNA for the detection of unabundant RNAs
whereas the PCR assays described in this study measured
three separate RNAs in a total of 500 ng of total RNA
(100 ng into each reverse transcription assay). If required, a
larger number of RNAs could be measured using the same
amount of RNA simply by increasing the number of com-
peting RNAs added to the reverse transcription reaction.
Furthermore, we believe that there is scope for increasing the
sensitivity of the reaction by reducing the amount of RNA
added to the reverse transcription reaction and/or increasing
the number of PCR cycles.
These assays are, however, currently sufficiently sensitive to
detect low levels of mRNA expression. We have for instance
confirmed our previous observation (May and Westley, 1988)
that T47D cells express the pNR-2/pS2 mRNA at low levels
whereas others have failed to detect expression of this RNA
in T47D using conventional hybridisation methods.
Quantitative nature ofdata generated by competitive
RT-PCR
Competitive RT-PCR measures the absolute amount of a
mRNA in an RNA sample. This facilitates comparison of
data between laboratories and experiments. Other PCR pro-
tocols as well as methods involving hybridisation such as
Northern blotting and RNase protection suffer from the
disadvantage that values are always relative and it is
therefore difficult to compare data between experiments.
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Despite the fact that previously used methods give im-
precise quantitation, estimates of the abundance of the three
mRNAs in this study are reasonably consistent with pre-
viously published data. For instance, the abundance of the
pNR-2/pS2 mRNA was estimated to be 3.7 pg 100 ng-1 total
RNA which is approximately 0.2% of mRNA assuming
mRNA comprises 2% of total RNA. This is similar to our
previous estimates based on the abundance of pNR-2 recom-
binants in a cDNA library (May and Westley, 1988). The
estimates for the abundance of the oestrogen receptor and
progesterone receptor are higher than estimates ofabundance
based on the number of recombinants obtained from cDNA
libraries. The reason for this is not known but the cDNAs
may have been underrepresented in the libraries.
Advantages ofcompetitive RT-PCR over conventional
methods
The aim of this study was to develop competitive RT-PCR
assays that would permit measurement of the target mRNAs
in the small numbers of tumour cells that are obtained by
FNA. As discussed above, conventional methods for measur-
ing RNA levels are not sufficiently sensitive. Typically 1 [Lg
or less of RNA is recovered from an aspirate and this would
not provide enough RNA for even one Northern transfer.
Traditionally, levels of the oestrogen receptor and pro-
gesterone receptor proteins have been measured by radioli-
gand assay. This requires sufficient amounts of tumour for
the preparation of cytosol and has prohibited their measure-
ment even for smaller palpable tumours. More recently,
ELISA methods have become available for the measurement
of the steroid receptors and pNR-2/pS2. Although more
sensitive, they still require sufficient tumour tissue for the
preparation of cytosol. Thus none of the commonly used
biochemical assays have found widespread use in the
measurement of these markers in cells obtained by FNA.
Immunohistochemistry is a powerful method for detecting
protein expression in tumour cells and has become more
widely used as the availability of antibodies has increased.
Indeed antibodies are available against the oestrogen and
progesterone receptor proteins and against the pNR-2/pS2
protein that react in sections from both formalin-fixed and
frozen tissue. This technique is rarely constrained by the
amount of tissue available, gives valuable information on the
pattern of expression within tissues and has been described
for cells obtained by FNA for both oestrogen receptor
(Crawford et al., 1985; Flowers et al., 1985; Coombes et al.,
1987; Gaskell et al., 1989; Davis et al., 1991) and pNR-2/pS2
(Wilson et al., 1994). The major disadvantage of immunohis-
tochemistry is its lack of quantitation and the requirement
for antibodies that react well in tissue sections. Although a
number of scoring methods have been used which take into
account the number of positive cells as well as the intensity
of staining, most studies use crude relatively subjective scor-
ing systems. The lack of quantitative information does not
allow retrospective analysis of data for optimal cut-off values
and cannot identify tumours with high levels of expression
that have the highest probability of responding to endocrine
therapy. In contrast, competitive RT-PCR provides an att-
ractive alternative to immunohistochemistry which can pro-
vide quantitative information and has the advantage that it
does not require the development or purchase of specialist
antibodies. The only constraint on setting up a competitive
PCR assay is the availability of the sequence of the gene to
be analysed. The competitive PCR assay may, in the future,
be adaptable to RNA extracted from cells obtained by mic-
rodissection of tissue sections.
In conclusion, we have developed highly sensitive, quan-
titative, competitive RT-PCR assays for the measurement of
the oestrogen receptor, progesterone receptor and pNR-2/
pS2 mRNAs. We suggest that these assays will be invaluable
for predicting the potential benefit of endocrine therapy to
individual patients and should enable rational decisions con-
cerning therapy to be taken on material obtained at the time
of diagnosis.Measurement of oestrogen response by RT-PCR
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